Russell Schundler Sells 2,576 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,576 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the transaction, the general counsel now directly owns 486,048 shares of the company’s stock, valued at $5,399,993.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Russell Schundler also recently made the following trade(s):

• On Tuesday, September 3rd, Russell Schundler sold 710 shares of Liquidia stock. The shares were sold at an average price of $9.50, for a total transaction of $6,745.00.

Liquidia Stock Up 2.2 %

LQDA stock opened at $11.63 on Thursday. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The stock has a market capitalization of $888.69 million, a P/E ratio of -7.46 and a beta of 0.22. The firm has a 50-day simple moving average of $10.42 and a 200-day simple moving average of $11.97.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million for the quarter, compared to analysts’ expectations of $7.92 million. On average, analysts expect that Liquidia Co. will post -1.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Lifesci Capital assumed coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company. HC Wainwright cut their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. BTIG Research cut their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Monday, August 19th. Finally, Bank of America cut their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Trading of Liquidia

Large investors have recently bought and sold shares of the business. Quest Partners LLC purchased a new stake in Liquidia during the 2nd quarter valued at about $27,000. Hilltop National Bank purchased a new stake in Liquidia during the 2nd quarter valued at about $33,000. Whitcomb & Hess Inc. grew its stake in Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after acquiring an additional 1,074 shares in the last quarter. Deuterium Capital Management LLC purchased a new stake in Liquidia during the 2nd quarter valued at about $120,000. Finally, DMC Group LLC acquired a new position in Liquidia in the 2nd quarter valued at about $122,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).